Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

BACKGROUND

Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus.

METHODS

In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new S. aureus bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments. Safety was also assessed.

RESULTS

Of 390 patients who underwent randomization, 387 (189 in the ceftobiprole group and 198 in the daptomycin group) had confirmed S. aureus bacteremia and received ceftobiprole or daptomycin (modified intention-to-treat population). A total of 132 of 189 patients (69.8%) in the ceftobiprole group and 136 of 198 patients (68.7%) in the daptomycin group had overall treatment success (adjusted difference, 2.0 percentage points; 95% confidence interval [CI], -7.1 to 11.1). Findings appeared to be consistent between the ceftobiprole and daptomycin groups in key subgroups and with respect to secondary outcomes, including mortality (9.0% and 9.1%, respectively; 95% CI, -6.2 to 5.2) and the percentage of patients with microbiologic eradication (82.0% and 77.3%; 95% CI, -2.9 to 13.0). Adverse events were reported in 121 of 191 patients (63.4%) who received ceftobiprole and 117 of 198 patients (59.1%) who received daptomycin; serious adverse events were reported in 36 patients (18.8%) and 45 patients (22.7%), respectively. Gastrointestinal adverse events (primarily mild nausea) were more frequent with ceftobiprole.

CONCLUSIONS

Ceftobiprole was noninferior to daptomycin with respect to overall treatment success in patients with complicated S. aureus bacteremia. (Funded by Basilea Pharmaceutica International and the U.S. Department of Health and Human Services; ERADICATE ClinicalTrials.gov number, NCT03138733.).

[MICROECOLOGICAL CHANGES IN THE INTESTINE AND ITS EFFECT ON THE CONDITION OF HARD TISSUES OF TEETH IN ADOLESCENCE]

On the background of microecological changes in the gastrointestinal tract, mineral and protein metabolism is disrupted, biochemical changes occur in the phosphorus-calcium metabolism in the bones of the skeleton and hard tissues of the teeth. The aim of the research was to study the activity of the caries process, characterized by progressive decalcification, under conditions of microecological changes in the intestine and its effect on the processes of endogenous calcium assimilation in adolescence. Within the frames of the research 68 adolescents aged 11 to 17 years with various degrees of pathology of the gastrointestinal tract were examined. The data of the performed studies showed that in patients with more severe changes in the intestinal micro flora, the prevalence and intensity of dental caries are significantly higher (83.4% on average DMFT 5.0) than in adolescents with mild dysbiosis (71.8% DMFT 3.2% ), and in the patients with normal intestinal micro flora - the parameters were minimal. Estimating and comparing the interrelation between the incidence of caries and the presence of diseases of the gastrointestinal tract in adolescents, a directly proportional dependence of the DMF index on age was found, but the greatest increase in the individual level of incidence of dental caries (SIC) was observed in adolescents aged 14-16 (SIC=0,42) with severe gastrointestinal pathology GIT. Thus, significant changes in dental status detected in adolescents with pathology of the gastrointestinal tract confirm the validity of complex treatment and preventive dental care, considering the processes occurring in the body and the oral cavity, as well as the systematic, purposeful dental care and the allocation of patients with gastrointestinal pathology (GIT) in a separate group.

Hospital-Based Surveillance for Infectious Etiologies Among Patients with Acute Febrile Illness in Georgia, 2008-2011

Information on the infectious causes of undifferentiated acute febrile illness (AFI) in Georgia is essential for effective treatment and prevention. In May 2008, a hospital-based AFI surveillance was initiated at six hospitals in Georgia. Patients aged ≥ 4 years with fever ≥ 38°C for ≥ 48 hours were eligible for surveillance. Blood culture and serologic testing were conducted for Leptospira spp., Brucella spp., West Nile virus (WNV), Crimean-Congo hemorrhagic fever virus, Coxiella burnetii, tick-borne encephalitis virus (TBEV), hantavirus, Salmonella enterica serovar Typhi (S. Typhi), and Rickettsia typhi. Of 537 subjects enrolled, 70% were outpatients, 54% were males, and the mean age was 37 years. Patients reported having fatigue (89%), rigors (87%), sweating (83%), pain in joints (49%), and sleep disturbances (42%). Thirty-nine (7%) patients were seropositive for R. typhi, 37 (7%) for Brucella spp., 36 (7%) for TBEV, 12 (2%) for Leptospira spp., 10 (2%) for C. burnetii, and three (0.6%) for S. Typhi. None of the febrile patients tested positive for WNV antibodies. Of the patients, 73% were negative for all pathogens. Our results indicate that most of the targeted pathogens are present in Georgia, and highlight the importance of enhancing laboratory capacity for these infectious diseases.

[Dysbiosis and its consequences on oral cavity in children and adolescents]

Gastrointestinal tract (GIT) diseases in children are often accompanied by changes in oral cavity, which is caused by common function of GIT and oral cavity organs. During last years, the number of dysbiosis of various severities has dramatically increased, which directly affects the oral cavity - dental hard tissue mineralization, especially in children and adolescents. The aim of our study was to identify the frequency of dysbiosis in children and adolescents and its influence on dental and general health. 279 patients aged 1 - 17 years were examined. Examinations have shown, that in patients with I-II degree dysbiosis spread and intensity (DMF index) of dental caries is significantly lower - 58,2% and 2,7 intensity, compared to III-IV degree dysbiosis, where 71,8% have caries with 4,2 intensity. According to this, dental and general health status in children and adolescents is highly dependent on severity of GI tract pathologies, particularly on qualitative and/or quantitative content of microbyotes of GI tract.

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C

Increased rates of apoptosis (programmed cell death) have been demonstrated in many hepatic diseases including chronic hepatitis C. IDN-6556 is a potent inhibitor of caspases, the proteases that execute apoptosis. In a prior phase 1 study, IDN-6556 lowered aminotransferase activity in a small number of patients with liver impairment. The purpose of this study was to further explore the effect of IDN-6556 in patients with liver disease in a multicenter, double-blind, placebo-controlled, dose-ranging study with a 14-day dosing period. A total of 105 patients were enrolled in the study; 79 received active drug; 80 patients had chronic hepatitis C and 25 had other liver diseases including nonalcoholic steatohepatitis (NASH), hepatitis B, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). IDN-6556 doses ranged from 5 mg to 400 mg daily, given from 1 to 3 times per day. In the HCV patients, all doses of IDN-6556 significantly lowered ALT and AST (P = 0.0041 to P < 0.0001 for various dosing groups in Wilcoxon tests comparing IDN-6556 to placebo), with the exception of the lowest dose. Declines in aminotransferase activity were also seen in patients with NASH but effects were not apparent in the small number of other liver diseases. Adverse experiences were not different between IDN-6556 and placebo. There were no clinically meaningful changes in other laboratory parameters. In particular, mean HCV RNA levels did not show significant changes.

CONCLUSION

Oral IDN-6556, given for 14 days, significantly lowered aminotransferase activity in HCV patients and appeared to be well tolerated. Longer studies to assess potential effects of IDN-6556 on liver inflammation and fibrosis are merited.